News
SNDX
8.86
+1.43%
0.13
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
Seeking Alpha · 5h ago
Weekly Report: what happened at SNDX last week (0630-0704)?
Weekly Report · 1d ago
SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Weekly Report: what happened at SNDX last week (0623-0627)?
Weekly Report · 06/30 09:02
William Meury Resigns from Syndax Pharmaceuticals Board
TipRanks · 06/26 13:17
Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG
TipRanks · 06/25 11:35
FDA Grants Priority Review To Syndax's Revuforj For R/R MNPM1 Acute Myeloid Leukemia Treatment
NASDAQ · 06/25 01:49
Syndax Gets Priority Review for Leukemia Drug Application
Dow Jones · 06/24 20:15
Syndax granted priority review for Revuforj sNDA by FDA
TipRanks · 06/24 20:10
Syndax Pharmaceuticals Announces That The FDA Has Granted Priority Review For Its Supplemental New Drug Application For Revuforj In Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
Benzinga · 06/24 20:03
Syndax's Revumenib Granted FDA Priority Review Under RTOR Program; PDUFA Date Set For October 25, 2025
Benzinga · 06/24 20:02
SYNDAX PHARMACEUTICALS INC - PDUFA ACTION DATE SET FOR OCTOBER 25, 2025
Reuters · 06/24 20:01
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
Barchart · 06/24 15:01
Weekly Report: what happened at SNDX last week (0616-0620)?
Weekly Report · 06/23 09:02
Weekly Report: what happened at SNDX last week (0609-0613)?
Weekly Report · 06/16 09:02
Syndax Pharmaceuticals (SNDX) Receives a Buy from Barclays
TipRanks · 06/16 08:15
Syndax Pharmaceuticals (SNDX) Gets a Buy from TD Cowen
TipRanks · 06/13 11:55
Bank of America Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
TipRanks · 06/13 09:55
Promising Potential of Syndax Pharmaceuticals’ Revuforj Drives Buy Rating
TipRanks · 06/13 09:26
Syndax reports publication of revumenib data from BEAT AML trial
TipRanks · 06/12 16:10
More
Webull provides a variety of real-time SNDX stock news. You can receive the latest news about Syndax Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.